Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire

被引:50
作者
Coyne, Karin S. [1 ]
Soliman, Ahmed M. [2 ]
Margolis, Mary Kay [1 ]
Thompson, Christine L. [1 ]
Chwalisz, Kristof [2 ]
机构
[1] Evidera, Bethesda, MD USA
[2] AbbVie Inc, N Chicago, IL USA
关键词
Health-related quality of life; HRQL; HRQoL; psychometric validation; recall period; UFS-QoL; uterine fibroids; INTRAINDIVIDUAL CHANGES; PERIOD;
D O I
10.1080/03007995.2016.1248382
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the psychometric performance of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire (UFS-QoL), a patient measure of the severity of uterine fibroid (UF) symptoms and their impact on health-related quality of life (HRQL). Methods: This was a retrospective analysis of phase 2a data from pre-menopausal women with heavy menstrual bleeding associated with UF. Participants completed the UFS-QoL at Baseline, Treatment Month 3, and Follow-up Month 3 and a daily diary with a Menstrual Bleeding Scale and the UF Daily Symptom Scale throughout the study duration. Descriptive statistics were performed on patient demographic characteristics; analyses were conducted to assess the internal consistency reliability, validity, and responsiveness of the UFS-QoL 4 week recall version. Results: A total of 271 women were enrolled with a mean age of 41.8 years; 74% were black. The UFS-QoL demonstrated excellent internal consistency reliability, with Cronbach's alpha coefficient values >0.70 for each subscale at each study visit. Results indicated good concurrent validity with the UF Daily Symptom Scale items. The women with amenorrhea at Treatment Month 3 had significantly better scores on all UFS-QoL subscales and HRQL Total than women with menstrual bleeding, indicating acceptable discriminant validity. Mean subscale change scores from Baseline to Treatment Month 3 were 19.2 to 39.8. Effect sizes were moderate to large (0.53 to 1.86), demonstrating responsiveness to change. Limitations: As this study is a post hoc validation of the 4 week recall UFS-QOL, it is limited to the clinical trial data available and does not include a direct comparison to the 3 month recall version of UFS-QOL. Conclusions: The 4 week recall version of the UFS-QoL demonstrated good internal consistency reliability, concurrent validity, and responsiveness and is psychometrically comparable to the original 3 month recall UFS-QoL.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 2009, FED REGISTER, V74, P65132
[2]   Clinical features of myomas [J].
Bukulmez, O ;
Doody, KJ .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2006, 33 (01) :69-+
[3]  
Cohen J, 2013, Statistical power analysis for the behavioral sciences, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
[4]   Further Validation of the Uterine Fibroid Symptom and Quality-of-Life Questionnaire [J].
Coyne, Karin S. ;
Margolis, Mary Kay ;
Bradley, Linda D. ;
Guido, Richard ;
Maxwell, G. Larry ;
Spies, James B. .
VALUE IN HEALTH, 2012, 15 (01) :135-142
[5]   The psychometric validation of a 1-week recall period for the OAB-q [J].
Coyne, Karin S. ;
Gelhorn, Heather ;
Thompson, Christine ;
Kopp, Zoe S. ;
Guan, Zhonghong .
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2011, 22 (12) :1555-1563
[6]  
CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297, DOI DOI 10.1007/BF02310555
[7]   Daytime Sleepiness in Parkinson's Disease: A Reappraisal [J].
De Cock, Valerie Cochen ;
Bayard, Sophie ;
Jaussent, Isabelle ;
Charif, Mahmoud ;
Grini, Magda ;
Langenier, Muriel Croisier ;
Yu, Huan ;
Lopez, Regis ;
Geny, Christian ;
Carlander, Bertrand ;
Dauvilliers, Yves .
PLOS ONE, 2014, 9 (09)
[8]   Use of a Medication Quantification Scale for Comparison of Pain Medication Usage in Patients with Complex Regional Pain Syndrome (CRPS) [J].
Gallizzi, Michael A. ;
Khazai, Ravand S. ;
Gagnon, Christine M. ;
Bruehl, Stephen ;
Harden, R. Norman .
PAIN MEDICINE, 2015, 16 (03) :494-500
[9]  
Gliklich R.E., 2011, Identification of future needs in the comparative management of uterine fibroid disease. A report on the priority-Setting process, preliminary data analysis
[10]  
Gretz H, 2008, AM J OBSTET GYNECOL, V199